Welcome visitor Log In - or - Register
(
0 items /
$0.00
)
View Cart
Check Out
four ways
Quick Search:
Skip Navigation LinksHome > Kinase Inhibitors > EGFR Mutants > AZD9291 (Osimertinib)
AZD9291 (Osimertinib)
AZD9291 (Osimertinib) is an oral, irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma, while sparing wild-type EGFR. Thus, AZD9291 potently inhibits EGFR phosphorylation in EGFRm+ (e.g. PC9; <25nM) and EGFRm+/T790M (e.g. H1975; <25nM) cell lines in vitro, whilst demonstrating much less activity against wild-type EGFR lines (e.g. LoVo; >500nM). It is currently in clinical trials.) is an oral, irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma, while sparing wild-type EGFR. Thus, AZD9291 potently inhibits EGFR phosphorylation in EGFRm+ (e.g. PC9; <25nM) and EGFRm+/T790M (e.g. H1975; <25nM) cell lines in vitro, whilst demonstrating much less activity against wild-type EGFR lines (e.g. LoVo; >500nM). It is currently in clinical trials.
Catalog NO: CT-A9291
Synonym: Mereletinib
CAS NO: 1421373-65-0
Mol. Formula: C28H33N7O2
MW: 499.6
** 99.8%, in vivo Grade material. An off-white to pale-yellow powder (picture attached), recrystallized, clean (all QC Docs attached), with a spot-on high-precision Quantitative Microanalysis. Bulk stock! Same day shipping.